Mr. Michael R. Minogue is the Chief Executive Officer, President and Chairman of Abiomed Inc. (NASDAQ: ABMD). Since joining in 2004, Mr. Minogue transitioned the company’s mission to heart muscle recovery with the acquisition and development of new technologies such as Impella®, the world’s smallest heart pump. During Mr. Minogue’s tenure, Abiomed has grown by 4,000 percent in market capitalization. The Company is one of the fastest growing, GAAP profitable med tech companies with no debt. Abiomed has earned over 30 global regulatory approvals on new products in the United States, Europe, Japan, China and other countries. Abiomed employs approximately 1,000 people with facilities in Danvers, Massachusetts, Aachen and Berlin, Germany and Tokyo, Japan. In 2017, Abiomed was ranked #4 on Fortune Magazine’s list of the top 100 fastest growing companies in the world.
In addition to his responsibilities at Abiomed, Mr. Minogue currently represents the medical device industry by serving on the executive board of directors for AdvaMed and as Chairman of the Medical Device Innovation Consortium (MDIC), a public-private partnership between industry, government and patient advocacy organizations. He was also recently appointed to Insulet Corporation's Board of Directors and serves on the Board of Managers for Bioventus LLC.
Mr. Minogue is the Chairman of the Governor’s Advisory Council on Veterans’ Services for the Commonwealth of Massachusetts, and is the Co-Founder and Chairman of the Mentoring Veterans Program (MVP) (www.mvpvets.org), a 501(c)(3) nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the life sciences industries. Additionally, Mr. Minogue serves on a committee for the Massachusetts Catholic Schools Foundation and recently stepped down as Chairman of the Board of Directors for MassMEDIC after ten years of service. He formerly served on the board for LifeCell (LIFC) before it was acquired in 2008.
Before joining Abiomed, Mr. Minogue spent 11 years with General Electric Healthcare, where he held numerous leadership positions and developed expertise in sales, marketing, product development, information technologies and software/service operations around diagnostic imaging of cancer and cardiovascular disease. He holds three patents.
Mr. Minogue served as an Infantry officer in the U.S. Army, which included multiple distinctions including Airborne, RANGER, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his Master of Business Administration from the University of Chicago.
Mr. Minogue is married with five children and enjoys reading, mentoring, running, coaching, skiing and playing sports.
Mr. Marc Began joined Abiomed in June 2018 and serves as vice president, general counsel, and secretary responsible for leading the company’s legal and compliance functions worldwide. Mr. Began has worked as a lawyer for more than 20 years, supporting various sectors of the life science industry, including pharmaceuticals, medical devices, and biotechnology. He joined Abiomed from Boehringer Ingelheim where he was vice president of intellectual property responsible for medical device, pharmaceutical, and biologic intellectual property issues.
Before joining Boehringer Ingelheim, Mr. Began held various positions of increasing responsibility at Novo Nordisk during a 15 year period. As assistant general counsel, he oversaw complex litigation matters. He also supported strategic transactions and business development. Prior to that, as assistant chief IP counsel, he managed global patent portfolios and enforcement strategy. Before joining Novo Nordisk, Mr. Began was an associate at the law firms of Sullivan & Cromwell and White & Case in New York where he handled a broad range of legal matters, including litigation, intellectual property, corporate transactions, regulatory and compliance.
Mr. Began earned a Juris Doctor degree from Albany Law School at Union University and holds a Bachelor of Science degree in mechanical engineering from Rensselaer Polytechnic Institute. He is also a licensed professional engineer and previously practiced engineering with the New York State Department of Environmental Conservation.
Dr. Seth Bilazarian joined Abiomed in 2015 and serves as our Chief Medical Officer. He is a clinical and interventional cardiologist and has performed coronary and peripheral interventions at Lahey Clinic, Boston University Medical Center, Massachusetts General Hospital and was Director of the Cardiac Catheterization Laboratory (Cath Lab) and Chief of the Cardiovascular Steering Committee at Lawrence General. He also served on the faculty as an instructor in medicine at Harvard Medical School. In 2008, he was appointed as physician advisor to the cardiac device panel of the Food & Drug Administration. Dr. Bilazarian received a Bachelor of Science in Engineering in Chemical Engineering from Tufts University and MD from University of Massachusetts Medical School. He completed his internship and residency at The Johns Hopkins Hospital in Baltimore, and cardiology and interventional cardiology fellowship at Boston University Hospital and Boston City Hospital. Dr. Bilazarian is board certified in cardiovascular medicine, nuclear cardiology, vascular ultrasound, interventional cardiology, and vascular and endovascular medicine.
Ms. Kelley Boucher joined Abiomed in September 2016. Prior to joining Abiomed, Ms. Boucher was the Head of Human Resources for Corporate Divisions at Shire Pharmaceuticals where she held multiple positions and managed the HR component of several acquisitions. Ms. Boucher has served as a Principal Consultant for Clockwork Consulting and has held Human Resources roles at Syntonix Pharmaceuticals and Digitas. Ms. Boucher brings significant experience leading organizational transformation, enabling growth through strategic talent acquisition and developing a high performance culture with a purpose. Ms. Boucher holds a Bachelor of Arts from Cornell University.
Mr. William J. Bolt joined Abiomed in June 1982 and currently serves as the Senior Vice President of Quality, Regulatory and Clinical Operations and as such, is responsible for the global management of the clinical trial and research, regulatory and quality functions. Over the last 10 years, he was responsible for the 510(k) and later the PMA approvals for the Impella platforms. From 2006 to early 2015, he ran Global Product Operations, which included the engineering, quality, product development and regulatory functions. He was responsible for our quality and service functions from 2003-2006 and led the AbioCor Total Artificial Heart program, BVS and AB5000 development from 1999-2003, as well as all product development and engineering activities on the Abiomed temporary ventricular assist devices over that same timeframe. From 1994 to 1998, he was the President of our former dental subsidiary, ABIODENT. Prior to that, he served the company in various roles, from Vice President of Engineering to Vice President of Operations and was responsible for the first commercial product developed by Abiomed, the BVS 5000. Mr. Bolt received both his Bachelor of Science in Electrical Engineering and Master of Business Administration from Northeastern University.
Mr. Andrew J. Greenfield is a Vice President and General Manager at Abiomed, Inc. responsible for the Healthcare Solutions and Global Marketing organizations. Mr. Greenfield has served as an Executive Officer of Abiomed since 2005 where he leads a broad spectrum of strategic initiatives including patient advocacy, government affairs, health economics and reimbursement, communications, clinical marketing, service operations and new market development.
Mr. Greenfield has spent over 20 years in leadership positions for advanced technology companies including Abiomed, GE Healthcare and Boeing with a particular focus on expanding patient access to leading edge technology designed to treat cardiovascular disease, the #1 killer in the world.
He is currently on the Board of Directors for MassMEDIC in Boston, MA, a public-private partnership that coordinates the resources used in managing medical devices to improve patient access to cutting-edge medical technology. He is a past executive committee member with the Medical Device Innovation Consortium (MDIC) which is advancing safer and more cost-effective innovations that benefit patients through a collaboration between the Centers for Medicare & Medicaid (CMS), Food and Drug Administration (FDA), industry and patients.
Mr. Greenfield received his Bachelor degree in Finance from the University of Illinois and Masters of Business Administration from St. Louis University. He is also a certified Master Blackbelt in Six Sigma and Change Acceleration Process from GE. Originally from Forreston, Illinois, he now resides in Massachusetts with his family.
Mr. Michael G. Howley joined Abiomed in March 2009 as Vice President and General Manager, Global Sales. Prior to joining us, Mr. Howley spent 20 years at GE Healthcare. From February 2006 to February 2009, he was General Manager at GE Healthcare, overseeing the Americas X-ray and Interventional Radiology division. From April 2004 to February 2006, Mr. Howley held the General Manager position for the Clinical Information Systems at GE. From October 2002 to April 2004, he was the Americas Sales Manager of Functional and Molecular Imaging. Prior to this role, Mr. Howley held several other national and regional sales positions at GE, beginning his tenure with the company in 1989. Mr. Howley has a Bachelor of Science in Business Administration and Marketing from Auburn University.
Dr. Raess joined Abiomed, Inc. in 2006 and is responsible for advising Abiomed’s customers on best practices in patient care and has additional responsibilities in product development for Abiomed’s lifesaving circulatory support technologies.
Prior to joining Abiomed, Dr. Raess was with the Cardiac and Vascular Surgery Associates (CVSA) Group, a private medical practice specializing in cardiothoracic surgery with St. Francis Hospital and The Indiana Heart Hospital, both in Indianapolis. During his 20-year tenure at CVSA, and more than 10 years using Ventricular Assist Devices (VADs), Dr. Raess worked extensively with Abiomed technology, having supported more than 50 patients on Abiomed’s BVS®5000 Biventricular Support System and the AB5000™ Circulatory Support System. Further, he has consulted for the company over the years beginning with the initial clinical trials for the BVS®5000 in 1989, which was published in the peer-reviewed journal the Annals of Thoracic Surgery.
Dr. Raess received his Medical Degree from the Ohio State University College of Medicine and completed his residency at Indiana University School of Medicine, where he was also an Assistant Professor of Surgery in the Division of Cardiothoracic Surgery. Dr. Raess holds the distinction of being a Fellow of the American College of Cardiology and a Fellow of the American College of Surgeons.
Dr. Thorsten Siess joined Abiomed in 2005 upon its acquisition of Impella CardioSystems, AG, which he co-founded in 1998 and has served as Manager of R&D, then Chief Technology Officer. His work in the development and marketing of the Impella 2.5® heart pump and 5.0® heart pump in Europe led to their CE Mark approval. During his time at the University of Aachen he developed the Impella® technology which served as a platform for the entire Impella product portfolio. The products, which allow early intervention through a pencil-sized VAD, are now available in 1100 centers in 40 countries. Prior to founding Impella, Dr. Siess served as Scientist in the Biomedical Technology Team at Helmholtz-Institute of Biomedicine at the University of Aachen in Germany. Dr. Siess received a Ph.D. degree as well as his MASc in Mechanical Engineering from the University of Aachen.
Mr. Todd A. Trapp joined Abiomed from Watts Water Technologies, Inc., a $1.5B global manufacturing leader of innovative products to control the efficiency, safety and quality of water within residential and commercial applications, where he served as CFO since 2015. Prior to joining Watts Water Technologies, Mr. Trapp spent 13 years in a variety of financial and operational roles at Honeywell International Inc., a $40B diversified technology and manufacturing company. At Honeywell, Mr. Trapp served as Vice President of Financial Planning and Analysis, Chief Financial Officer of the Airlines Business Unit, Director of Finance for the Transportation Systems Division, Investor Relations Manager and other senior finance positions. Prior to joining Honeywell, Mr. Trapp held several treasury and finance operational roles at United Business Media, Inc. and Pearson, Inc. Mr. Trapp holds a BS in Accounting from Providence College and an MBA in Finance from Northeastern University.
Dr. David Weber joined Abiomed in April 2007 as the Chief Operating Officer. Prior to joining Abiomed, Dr. Weber served as General Manager, Aviation Business at GE Security—Homeland Protection from April 2005 until April 2007 where he led GE Security’s Aviation and Transportation Business and was responsible for product development, marketing and sales. From June 2004 until April 2005, he served as General Manager, MRI Marketing at GE Healthcare where he was responsible for strategic product planning, go-to-market and product launch activities including developing product roadmaps and introducing new product technologies to the market, and from March 2001 until June 2004, he served as Manager, Global High Field MRI Business, GE Medical Systems where he was responsible for new product planning and development. Dr. Weber has a B.S. in physics from Denison University, a Bachelor of Science in Nuclear Engineering from Columbia University, a Master of Science in Medical Physics from the University of Wisconsin-Madison, and a Doctor of Philosophy in Medical Physics from the University of Wisconsin-Madison.